HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

483.398

-13.360-2.69%

Number of Gainers:8

Number of Losers:22

Number of Flat:3

PE:- -

High:496.758

Open:496.758

Low:482.253

Close:496.758

Volume:27.35M

Turnover:662.42M

Market Cap:306.58B

Float Cap:273.56B

Loading ...

Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally

康宁杰瑞制药-B于9月4日斥资约49万港元回购5.6万股

Alphamab Oncology Files HKEX Next-Day Disclosure Return on Share Repurchase at HKD 8.79 Each

Zhaoke Ophthalmology Says Presbyopia Eye Drop Yuvezzi Meets Primary Endpoint in China Phase II Trial

China Galaxy Securities Forecasts High-Growth Prospects in Innovative Drug Sector Driven by Commercialization and Out-Licensing Deals

Assessing the Value of InnoCare's ICP-488 in the Psoriasis Market

Daiwa Highlights AKESO's HARMONi-2 Milestone, Bolstering Case for Global NSCLC Study Success

Healthcare Sector Poised for Continued Recovery, Buoyed by Strong Innovation and Upgraded Earnings Forecasts

Hong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B

Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment to the Co

Everest Medicines Gets China Nod for CARDAMYST Application

MT Newswires Live

ZYLOXTB (02190) Allocates HK$1.12 Million for Share Buyback on September 3

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback

Everest Medicines Says China NMPA Approves Cardamyst Nasal Spray for PSVT Conversion in Adults

Everest Medicines - Nmpa Approves Cardamyst (Etripamil) Nda for Psvt in Adults in China

THOMSON REUTERS

Ni Xin Boosts Stake in Edding Genor with 150,000 Share Purchase

GENFLEET-B Allocates HK$546,400 to Buy Back 20,000 Shares on September 3

Navigating the Investment Landscape Amid the Innovative Drug Surge

CMS Secures NMPA Nod for Ruxolitinib Cream's Expanded Use in Atopic Dermatitis

Apichope's Gout Drug Candidate Meets Primary Goal in Late-Stage China Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/BK1574/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":483.3978,"timestamp":1789093141798,"preClose":496.75812,"halted":0,"volume":27346561,"delay":0,"changeRate":-0.026895,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-13.360321,"latestTime":"09-11 10:19:02","open":496.75812,"high":496.75812,"low":482.25314,"amount":662417245,"amplitude":0.029199,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789099200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.703217,"peRate":164.740195,"turnoverRate":0.00104,"increases":8,"decrements":22,"flats":2,"marketCap":306582281024,"floatMarketCap":273561999768},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.029199,"preClose":496.75812,"low":482.25314,"pbRate":"3.703217","latestPrice":483.3978,"volume":27346561,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.00104,"peRate":164.740195,"marketCap":306582281024,"floatMarketCap":273561999768,"timestamp":1789093141798,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":22,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1188865864","title":"Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1188865864","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188865864?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:16","pubTimestamp":1788524178,"startTime":"0","endTime":"0","summary":"Hong Kong stocks ended the session firmly in positive territory, closing up 1.74% after a strong open, though momentum faded slightly into the close. The overnight surge on Wall Street, where all...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OEF","DPST","UDN","SPYI","NGHT","LU2399975544.HKD","BK4550","UBT","ISHG","VEXC","BK4588","DMAX","VCIT","BK4534","LU0348825331.USD","BK1161","BK1109","TNmain","HYGU","BWZ","BBLB","SMAX","SPXU","VOO","FAZ","LU0417516902.SGD","PBDC","BK1207","LQD","LQDU","VCSH","OOQB","09678","IE00BPRC5H50.USD","TLTW","IGOV","LU0417516738.SGD","VXUS","MESmain","MUNX","EBUF","IE00B543WZ88.USD","09926","LU1720050803.USD","WAMA","02714","GOLY","LU0348766576.USD","NEMD","SSO","UBmain","LU0348735423.USD","SHV","02698","AGG","SKRE","DBND","LU0540923850.HKD","BK4559","TLTX","SPYH","KBWB","SPXS","TBIL","LU0348767384.USD","TLH","BK1237","BOXX","VFH","SPYB","MUB","FLGV","KCAI","TYO","LU1961090484.USD","LU2476274308.USD","VGIT","HMOP","GOVT","HK0000165453.HKD","JPST","TSYW","USHY","HYG","SPYQ","HIBL","LU0417516571.SGD","LU0634319403.HKD","BBSB","BK4581","SH","MMAX","KURE","BND","TLT","XLF","EDV","LU2476274720.SGD","MYCN","TMF","VGSH","ZFmain","SPXL","HYGD","LU0348783233.USD","BK4535","IAT","BK4561","TIP","LU2778985437.USD","LU0348827113.USD","TBJL","KBE","SHY","MINT","VGLT","SGOV","SDS","BOND","TBT","IEI","LU0561508036.HKD","ESmain","SPUU","KRE","LIAJ","KRX","TFJL","ZBmain","LU1794554557.SGD","BK4585","BK4504","LQDD","LU2488822045.USD","BK1574","SPYU","JULD","BK1160","ZTmain","SPDN","YSPY","02419",".SPX","FEM","TLTI","IEF","OEX","IE00B5MMRT66.SGD","SPY","NELS","IVV","BSV","GBIL","BBIB","BWX","LU0348784397.USD","ZROZ","SPYM","EMPB","XBIL","UUP","SCHO","RAUS","XLRI","CIVG","BIL","UPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118036040","title":"康宁杰瑞制药-B于9月4日斥资约49万港元回购5.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118036040","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118036040?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:00","pubTimestamp":1788523218,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（09966）于2026年9月4日发布公告，披露其当日回购动作。公告显示，该公司在当天耗资49.243万港元，回购了5.6万股股份。此次回购行动体现了公司对自身价值的信心，并可能对市场情绪产生一定积极影响。","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339000","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return on Share Repurchase at HKD 8.79 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339000","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339000?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:54","pubTimestamp":1788522890,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return on share repurchase at HKD 8.79 eachAlphamab Oncology repurchased 56,000 ordinary shares on Sept. 4 for treasury, per HKEX next-day disclosure r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL2JKKnC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664336546","title":"Zhaoke Ophthalmology Says Presbyopia Eye Drop Yuvezzi Meets Primary Endpoint in China Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664336546","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664336546?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:39","pubTimestamp":1788518398,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology says presbyopia eye drop YUVEZZI meets primary endpoint in China Phase II trialZhaoke Ophthalmology reported its YUVEZZI presbyopia eye drop met the primary endpoint in a China Ph","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL5kNMcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","06622","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125606398","title":"China Galaxy Securities Forecasts High-Growth Prospects in Innovative Drug Sector Driven by Commercialization and Out-Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=1125606398","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125606398?lang=en_us&edition=fundamental","pubTime":"2026-09-04 16:42","pubTimestamp":1788511349,"startTime":"0","endTime":"0","summary":" China Galaxy Securities has released a research report indicating that after a significant pullback in the pharmaceutical sector during the first half of the year, valuations for both innovative and...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","06881","BK1147","159992","MEDX","BK1161","601881","IBBQ","BK0188","BK1564","BK1574","LNGR","BK0276","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143374133","title":"Assessing the Value of InnoCare's ICP-488 in the Psoriasis Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1143374133","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143374133?lang=en_us&edition=fundamental","pubTime":"2026-09-04 15:30","pubTimestamp":1788507030,"startTime":"0","endTime":"0","summary":"For innovative drug companies, valuation hinges on pipeline potential, and InnoCare's lead asset in the autoimmune space, the highly selective TYK2 allosteric inhibitor ICP-488 (Fadeucravacitinib),...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","688428","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155688836","title":"Daiwa Highlights AKESO's HARMONi-2 Milestone, Bolstering Case for Global NSCLC Study Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1155688836","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155688836?lang=en_us&edition=fundamental","pubTime":"2026-09-04 15:24","pubTimestamp":1788506656,"startTime":"0","endTime":"0","summary":"Daiwa has released a research report noting that the pre-specified interim overall survival (OS) analysis for AKESO's (09926) Phase III study of ivonescimab as a first-line treatment for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","LU2399975544.HKD","09926","LU0348825331.USD","IE00BPRC5H50.USD","BK1161","KURE","LU2476274720.SGD","LU0348783233.USD","LU0561508036.HKD","LU1794554557.SGD","LU1961090484.USD","IE00B543WZ88.USD","LU0634319403.HKD","LU0348827113.USD","LU0348735423.USD","LU0417516902.SGD","BK1574","LU0348784397.USD","LU0417516571.SGD","LU0540923850.HKD","LU2488822045.USD","LU0417516738.SGD","LU1720050803.USD","LU0348766576.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183163431","title":"Healthcare Sector Poised for Continued Recovery, Buoyed by Strong Innovation and Upgraded Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1183163431","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183163431?lang=en_us&edition=fundamental","pubTime":"2026-09-04 15:16","pubTimestamp":1788506182,"startTime":"0","endTime":"0","summary":"According to a research report from BOCOM INTL, the Hong Kong-listed healthcare sector charted an independent course in August, with the Hang Seng Healthcare Index climbing 9.3% against a 1.2%...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03329","ZECP","159938","BK1161","BK1515","BK1574","09939","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117075643","title":"Hong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B","url":"https://stock-news.laohu8.com/highlight/detail?id=1117075643","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117075643?lang=en_us&edition=fundamental","pubTime":"2026-09-04 09:12","pubTimestamp":1788484341,"startTime":"0","endTime":"0","summary":"According to the latest disclosure from the Hong Kong Stock Exchange, a notable change in share custody was recorded on September 3rd for GENFLEET-B (02595). The total market value of the shares held...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","02595","BK1574","159938","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664480867","title":"Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment to the Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2664480867","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664480867?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:56","pubTimestamp":1788447419,"startTime":"0","endTime":"0","summary":"Sept 3 (Reuters) - Milestone Pharmaceuticals Inc::*MILESTONE PHARMACEUTICALS ANNOUNCES NMPA APPROVAL OF ETRIPAMIL NASAL SPRAY FOR PSVT IN CHINA, MARKING FIRST REGULATORY APPROVAL OF ETRIPAMIL OUTSIDE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nRSD1Mvfn1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01952","BK1583","BK1574","BK4007","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874018","title":"Everest Medicines Gets China Nod for CARDAMYST Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874018","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874018?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:40","pubTimestamp":1788439214,"startTime":"0","endTime":"0","summary":"Everest Medicines  obtained approval for the new drug application of CARDAMYST from China's National Medical Products Administration.The drug is for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults, according to a Thursday Hong Kong bourse filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01952","BK1583","BK1574","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159831479","title":"ZYLOXTB (02190) Allocates HK$1.12 Million for Share Buyback on September 3","url":"https://stock-news.laohu8.com/highlight/detail?id=1159831479","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159831479?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:24","pubTimestamp":1788438277,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) declared that on September 3, 2026, the company repurchased 52,500 shares at an aggregate cost of roughly HK$1.1219 million.The shares were bought back at a price range of HK$21.18 to HK$21.52 each.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1574","BK1100","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874561","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874561","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874561?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:17","pubTimestamp":1788437861,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share buybackZylox-Tonbridge repurchased 52,500 H shares on Sept. 3, 2026 for treasury.Buyback price range HKD 21.18 to HKD 21.52; aggregate co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL70MPxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02190","BK1574","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664087437","title":"Everest Medicines Says China NMPA Approves Cardamyst Nasal Spray for PSVT Conversion in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2664087437","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664087437?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:15","pubTimestamp":1788437722,"startTime":"0","endTime":"0","summary":"Everest Medicines says China NMPA approves Cardamyst nasal spray for PSVT conversion in adultsChina’s NMPA cleared the NDA for CARDAMYST (etripamil) nasal spray to convert acute PSVT episodes to sinus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLbRghy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871033","title":"Everest Medicines - Nmpa Approves Cardamyst (Etripamil) Nda for Psvt in Adults in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871033?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:06","pubTimestamp":1788437196,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44V0KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176154423","title":"Ni Xin Boosts Stake in Edding Genor with 150,000 Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1176154423","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176154423?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:34","pubTimestamp":1788435274,"startTime":"0","endTime":"0","summary":"Recent data from the Hong Kong Stock Exchange reveals that on September 1, Ni Xin increased his holdings in EDDING GENOR (06998) by 150,000 shares at a price of HK$1.6489 per share, totaling...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","06998","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101393084","title":"GENFLEET-B Allocates HK$546,400 to Buy Back 20,000 Shares on September 3","url":"https://stock-news.laohu8.com/highlight/detail?id=1101393084","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101393084?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:24","pubTimestamp":1788434654,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced that on September 3, 2026, it spent HK$546,400 to repurchase 20,000 of its own shares.This buyback reflects the company's ongoing capital management strategy, as it...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","02595","159938","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135667303","title":"Navigating the Investment Landscape Amid the Innovative Drug Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1135667303","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135667303?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:20","pubTimestamp":1788430837,"startTime":"0","endTime":"0","summary":"As the innovative drug sector gains momentum, investors are keenly eyeing opportunities that align with this upward trend. The recent formation of a MACD golden cross signal, a key technical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","BK1574","06978","MEDX","IBBQ","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176808711","title":"CMS Secures NMPA Nod for Ruxolitinib Cream's Expanded Use in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1176808711","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176808711?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:04","pubTimestamp":1788429862,"startTime":"0","endTime":"0","summary":"CMS (00867) has announced that its subsidiary, Demei Pharma, obtained approval from China's National Medical Products Administration (NMPA) on September 2, 2026, for the New Drug Application (NDA) of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","IBBQ","BK1161","SG9999015952.SGD","BK4132","IE00BMCWC346.EUR","SG9999004220.SGD","SG9999015945.SGD","SG9999015978.USD","159992","SG9999015986.USD","BK1574","BK1191","BK1593","LU2488822045.USD","LNGR","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","AD","IE00BYV24P56.USD","00867","MEDX","IPOS","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148282007","title":"Apichope's Gout Drug Candidate Meets Primary Goal in Late-Stage China Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1148282007","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148282007?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:50","pubTimestamp":1788429022,"startTime":"0","endTime":"0","summary":"Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) has announced that its wholly-owned subsidiary, Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd., recently obtained top-line data from a Phase...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300723","IBBQ","159992","MEDX","06978","BK0239","BK1574","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":6,"totalSize":255,"code":"91000000","status":"200"}]}}